Spots Global Cancer Trial Database for Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma
Official Title: A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1401 Administered Weekly for 4 Weeks in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma
Study ID: NCT00634452
Conditions
Interventions
Study Description
Brief Summary: To establish the safety and tolerability profile of MDX-1401 in patients with relapsed or refractory Hodgkin's Lymphoma (HL).
Detailed Description:
Eligibility
Minimum Age: 12 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
ClinWorks Cancer Research Center, Charlotte, North Carolina, United States
Scott and White Memorial Hospital and Clinic, Temple, Texas, United States
West Virginia University, Morgantown, West Virginia, United States
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
